Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

The Leukemia & Lymphoma Society and Dana-Farber to bring clinical trials to local communities

  • Robert Soiffer, MD

    The Leukemia & Lymphoma Society (LLS) today joined Dana-Farber Cancer Institute in Boston to establish a network of sites for clinical trial testing of innovative blood cancer therapies in community oncology settings across the country.

    This groundbreaking Blood Cancer Research Partnership (BCRP) will bring clinical trials closer to where patients live and help to address one of the primary bottlenecks in the development of new cancer therapies: the need for more patients to take part in trials.

    “Having to travel long distances from home to a major medical center is a major deterrent to patients’ participation in cancer clinical trials,” said LLS Chief Mission Officer Louis J. DeGennaro, PhD. “Most cancer patients are treated by oncologists in their local community. This partnership will bring trials closer to where patients live. We are optimistic that this program will increase trial enrollment, more rapidly advance innovative blood cancer therapies and save lives.”

    Ten potential sites have been identified for the trials – in California, Colorado, Florida, Georgia, Maine, Minnesota, New Jersey, New York, Tennessee, and Washington State.

Posted on June 06, 2013

  • Robert J. Soiffer, MD
  • Research
  • Media Contacts

    If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email

    The Media Team cannot respond to patient inquiries. For more information, please see Contact Us.

  • New Patient Appointments

    For adults: 877-442-3324
    For children: 888-733-4662

    Make Appointment Online